AbCellera Biologics Announces $187M Public Offering Pricing

What Happened

• AbCellera Biologics Inc. announced on August 12, 2026 that it entered an underwriting agreement and priced an underwritten public offering. The offering consists of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 common shares at $9.74999 per warrant (exercise price $0.00001).
• The company estimates net proceeds of approximately $187.0 million after underwriting discounts, commissions and estimated offering expenses. The offering is being made under an existing Form S-3 shelf registration; closing is expected on or about August 14, 2026.

Key Details

• Shares offered: 17,435,897 common shares at $9.75 per share.
• Pre-Funded Warrants: up to 3,076,926 warrants priced at $9.74999 each; each exercisable for one share for $0.00001 (cashless exercise option available).
• Estimated net proceeds: approximately $187.0 million to the company.
• Limitations and lock-up: Pre-funded warrant exercises are subject to a 4.99% beneficial ownership cap per holder (adjustable up to 19.99% with notice); company and its officers/directors agreed to customary 60‑day lock-up post-agreement.

Why It Matters

• This offering raises substantial capital (about $187M net) which increases AbCellera’s cash resources. New shares and the potential issuance of warrant shares will increase the company’s outstanding shares and can dilute existing stockholders’ ownership.
• The immediate exercisability of the pre-funded warrants means additional shares could be issued quickly subject to ownership caps. The 60-day lock-up limits insider selling in the near term, which can affect short-term float and trading dynamics.